Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/22300
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLewis, Richard-
dc.contributor.authorPételle, Boris-
dc.contributor.authorCampbell, Matthew C-
dc.contributor.authorMacKay, Stuart-
dc.contributor.authorPalme, Carsten-
dc.contributor.authorRaux, Guillaume-
dc.contributor.authorSommer, J Ulrich-
dc.contributor.authorMaurer, Joachim T-
dc.date2019-11-02-
dc.date.accessioned2020-01-07T00:33:29Z-
dc.date.available2020-01-07T00:33:29Z-
dc.date.issued2019-12-
dc.identifier.citationLaryngoscope investigative otolaryngology 2019; 4(6): 703-707-
dc.identifier.issn2378-8038-
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/22300-
dc.description.abstractThis report describes the surgical implantation of a novel bilateral hypoglossal nerve stimulator (Genio system®, Nyxoah S.A., Belgium) and the successful treatment of a patient with moderate obstructive sleep apnea (OSA). Surgical technique description and case study report. The bilateral implantable stimulator (IS) simultaneously stimulates both genioglossus (GG) muscles to reduce airway obstruction. At night, patients wear an activation chip under their chin that wirelessly transmits energy to the implant and enables the nerve stimulation. Surgical implantation of the IS is performed under general anesthesia by making a small incision above the hyoid bone and dissecting through the platysma, mylohyoid, and geniohyoid muscles to the GG muscle. The hypoglossal nerve branches are then identified, followed by suturing the IS in place. The system was evaluated in an otherwise healthy, 60-year-old woman with moderate OSA (apnea hypopnea index (AHI): 25/hr, nadir O2 saturation: 78%). Appropriate stimulation settings were determined at 2-, 3-, and 6-months post implantation during polysomnography (PSG) and changes in apnea and hypopnea events and oxygen desaturation recorded. The surgery was well tolerated by the patient with an uneventful recovery. The PSG at 6 months showed that AHI per hour, obstructive apnea events per hour, hypopnea events per hour, and oxygen desaturation index have been reduced by 88%, 92%, 88%, and 97%, respectively, and nadir O2 saturation improved to 91%. The absence of complications and considerable reduction of apnea and hypopnea events in this case study help demonstrate the potential safety and efficacy of the bilateral hypoglossal nerve stimulator. 4.-
dc.language.isoeng-
dc.subjectObstructive sleep apnea-
dc.subjectbilateral-
dc.subjecthypoglossal nerve stimulation-
dc.subjectneuromodulation-
dc.titleImplantation of the nyxoah bilateral hypoglossal nerve stimulator for obstructive sleep apnea.-
dc.typeJournal Article-
dc.identifier.journaltitleLaryngoscope investigative otolaryngology-
dc.identifier.affiliationHôpital Tenon AP-HP Paris Franceen
dc.identifier.affiliationHollywood Private Hospital Perth Western Australia Australiaen
dc.identifier.affiliationInstitute for Breathing and Sleep, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationIllawarra ENT Head and Neck Clinic Wollongong New South Wales Australiaen
dc.identifier.affiliationWestmead Private Hospital Sydney New South Wales Australiaen
dc.identifier.affiliationNyxoah S.A. Mont-Saint-Guibert Belgium-
dc.identifier.affiliationHelios University Hospital Wuppertal University Witten/Herdecke - Wuppertal Germany-
dc.identifier.affiliationDivision Of Sleep Medicine, Department of ORL-HNS University Medicine Mannheim-
dc.identifier.doi10.1002/lio2.312-
dc.identifier.pubmedid31890891-
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.